Get started
Author

Maegan E. Hoover

Observed names: Maegan E Hoover, Maegan Hoover
ORCID: 0009-0006-7280-179X
Observed ORCID: 0009-0006-7280-179X
OpenAlex ID: A5033027592
Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15
2021 · Shannon L. McArdel, Anne-Sophie Dugast, et al. · Cancer Immunology Immunotherapy · 27
PDF
208 RTX-224, an engineered allogeneic red cell therapeutic expressing 4–1BBL and IL-12, activates immune cells in blood and spleen to promote tumor growth inhibition in mice
2021 · Anne-Sophie Dugast, Shannon McArdel, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Abstract 3272: RTX-212, an allogeneic red cell therapeutic expressing 4-1BBL and IL-15TP, exhibits potent in vitro and in vivo activity and a favorable safety profile
2019 · Anne-Sophie Dugast, Shannon McArdel, et al. · Immunology · 2
Systematic analysis of T cell responses specific to the Epstein-Barr virus proteome using ATLAS™
2017 · Johanna K Kaufmann, Biao Liu, et al. · The Journal of Immunology · 2
An allogeneic CD19 targeted Engineered Treg approach for treating B cell mediated autoimmune diseases 2260315
2026 · Payam Zarin, Christopher Moore, et al. · The Journal of Immunology · 1
144 RTX-240, an allogeneic engineered red blood cell expressing 4–1BBL and IL-15TP, promotes NK cell functionality in vitro and in vivo
2020 · Anne-Sophie Dugast, Shannon McArdel, et al. · Journal for ImmunoTherapy of Cancer · 1
Abstract 3272: RTX-212, an allogeneic red cell therapeutic expressing 4-1BBL and IL-15TP, exhibits potent in vitro and in vivo activity and a favorable safety profile
2019 · Anne-Sophie Dugast, Shannon McArdel, et al. · Cancer Research · 1
Regulatory T cell function and engineering for next generation cell therapies
2026 · Nathan W. Zammit, Martina Sassone-Corsi, et al. · Frontiers in Immunology
PDF
A synthetic NKG2A engager enables long-term persistence of HLA-deficient allogeneic engineered Tregs
2026 · Tingxi Guo, Kaya R Epstein, et al. · EMBO Molecular Medicine
PDF
ST2 enforces a ‘repair-ready’ Treg phenotype that homes to and ameliorates neuroinflammation 2260164
2026 · Nathan Zammit, Maegan Hoover, et al. · The Journal of Immunology
Modular engineering of Tregs for the treatment of inflammatory and autoimmune diseases 2259867
2026 · Payam Zarin, Gene Uenishi, et al. · The Journal of Immunology
GNTI-932: A Targeted, Scalable, and Hypoimmune Allogeneic Engineered Treg therapy for the treatment of Inflammatory Bowel Disease 2251383
2026 · Martina Sassone-Corsi, Jennifer Yam, et al. · The Journal of Immunology
PDF
Allogeneic Tissue Tregs Improve Disease Outcome in Models of Acute Lung and Kidney Injury 2259889
2026 · Payam Zarin, Maegan Hoover, et al. · The Journal of Immunology
Adoptive transfer of allogeneic murine Engineered Regulatory T cells ameliorates disease in models of ischemic stroke and acute lung injury 3688
2025 · Payam Zarin, Maegan Hoover, et al. · The Journal of Immunology
PDF
CAR19 EngTregs offer broad capacity to modulate immune tolerance and improve safety in B and T cell mediated autoimmune disorders 3850
2025 · Victoria L. DeVault, Matteo Doglio, et al. · The Journal of Immunology
PDF
Engineered Tissue Tregs ameliorate inflammatory and ischemic diseases 3661
2025 · Maegan Hoover, Priya Saikumar Lakshmi, et al. · The Journal of Immunology
PDF
GNTI-823: Engineered Allogeneic Tissue Regulatory T Cells Ameliorate AKI via Immune Modulation and Tissue Repair
2025 · Payam Zarin, Maegan Hoover, et al. · Journal of the American Society of Nephrology
Abstract 3256: RTX-IL-12, an allogeneic red cell therapeutic expressing IL-12, exhibits potent in vitro and in vivo activity and favorable safety profile
2019 · Anne-Sophie Dugast, Enping Hong, et al. · Immunology
Abstract 3256: RTX-IL-12, an allogeneic red cell therapeutic expressing IL-12, exhibits potent in vitro and in vivo activity and favorable safety profile
2019 · Anne-Sophie Dugast, Enping Hong, et al. · Cancer Research
Works count: 19
Citation count: 37
H-index: 2
I10-index: 1
Year
Topic
Type